INTERLEUKIN-6 SERUM LEVELS IN PATIENTS WITH GYNECOLOGICAL TUMORS
INTERLEUKIN-6 SERUM LEVELS IN PATIENTS WITH GYNECOLOGICAL TUMORS
复制标题
DOI：
10.1002/ijc.2910570305
复制
发表时间：
1994-05-01
影响因子：
6.4
通讯作者：
MANCUSO, S
中科院分区：
文献类型：
--
作者：
SCAMBIA, G;TESTA, U;MANCUSO, S
对一大批妇科良性或恶性肿瘤患者血清IL-6水平进行了评价。结果与患者的临床病理特征及随访资料相关。采用高灵敏度免疫酶法测定血清IL-6水平，发现95%的正常健康女性血清IL-6水平在1.9-6 pg/ml范围内。在45例原发性上皮性卵巢癌患者中，53%的患者血清IL-6水平升高，而子宫内膜癌和宫颈癌患者的血清IL-6水平升高的情况较少（分别为37%和10%）。IL-6水平升高偶尔见于良性疾病患者。血清IL-6水平在卵巢癌诊断中的敏感性低于CA - 125。在癌症患者中，血清IL-6水平的升高与肿瘤的存在有关，因为所有术后患者的IL-6水平都明显下降。晚期卵巢癌患者术后IL-6水平与残留病变相关。9例卵巢癌患者腹水中均可见高水平的IL-6，但肿瘤细胞中未检测到IL-6 mRNA。这表明在卵巢癌中观察到的IL-6的增加是反应性的。与化疗有反应的患者相比，对化疗无反应的患者IL-6水平较高。单因素生存数据分析表明血清IL-6水平升高与不良预后相关。(C) 1994 Wiley-Liss, Inc。
Serum levels of IL-6 were evaluated in a large group of patients with benign or malignant gynecological tumors. The results obtained were correlated with the patients' clinicopathological features and follow-up data. Using a highly sensitive immunoenzymatic method for the evaluation of serum IL-6 levels, were observed that > 95% of normal healthy women exhibited values within the range of 1.9-6 pg/ml. Using a cut-off of 6 pg/ml, elevated levels of serum IL-6 were found in 53% of 45 patients with primary epithelial ovarian cancer and less frequently in patients with endometrial and cervical cancer (37% and 10% respectively). Elevated levels of IL-6 were occasionally seen in patients with benign disease. IL-6 serum levels appeared to be less sensitive than CA 125 in ovarian cancer diagnosis. In cancer patients, increased IL-6 serum levels were related to the presence of the tumor since all post-operative patients exhibited a marked decrease. In patients with advanced ovarian cancer post-operative levels of IL-6 correlated with residual disease. Very high levels of IL-6 were observed in the ascitic fluid of 9 ovarian cancer patients, but IL-6 mRNA was not detected in tumor cells. This suggests that the increased production of IL-6 observed in ovarian cancer is reactive. Higher levels of IL-6 were found in patients unresponsive to chemotherapy, as compared with responsive ones. Univariate analysis of survival data suggests that increased IL-6 serum levels correlate with negative prognosis. (C) 1994 Wiley-Liss, Inc.